Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Tag Archives: venture capital
Upcoming Webcast: Data Driven Laboratory Asset Management Programs
Unlock unknown capital and drive efficiency while improving quality and scientist experience
Wednesday, June 17, 2009 at 10 AM EST
With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify [...]
Posted in Webcast Also tagged Biotechnology, business, Economy of scale, Financial services, Investment, Investment management, Productivity Leave a comment
Conversation with Eisai’s Lonnel Coats
“The phones are ringing,†said Lonnel Coats, president of Eisai and a plenary speaker here at HBA’s Leadership Conference. “There’s a lot more opportunity, but also a lot more white noise.â€
Coats is referring to the pressure that cash-strapped biotechs are feeling to sell out and says he gets no less than five calls a day [...]

BIO Convention: Potemkin Pavilions and the Power of NICE